You are here:

Category: 1.5 Chronic bowel disorders

Name SMC ID No Manufacturer Status Sub. Type
 
infliximab (Remicade) 374/07 MSD Superseded Resubmission
budesonide (Cortiment) 1093/15 Ferring Pharmaceuticals Ltd Restricted Resubmission
infliximab 100mg powder for intravenous infusion (Remicade) 363/07 Schering-Plough Ltd Superseded Full submission
infliximab 100mg powder for intravenous infusion (Remicade) 364/07 Schering-Plough Ltd Superseded Full submission
beclometasone dipropionate 5mg (Clipper) 166/05 Trinity-Chiesi Pharmaceuticals Ltd Not Recommended Full submission
budesonide 2mg Rectal Foam (Budenofalk) 409/07 Dr Falk Pharma UK Accepted Abbreviated Submission
adalimumab 40mg solution for injection (Humira) 417/07 Abbott Laboratories Superseded Full submission
mesalazine (Asacol) 222/05 Procter and Gamble Accepted Abbreviated Submission
mesalazine (Asacol) 224/05 Procter and Gamble Accepted Abbreviated Submission
mesalazine (Asacol) 223/05 Procter and Gamble Accepted Abbreviated Submission
infliximab (Remicade) 448/08 Schering-Plough Ltd Superseded Full submission
mesalazine 1200mg gastro-resistant prolonged release tablet (Mezavant XL) 445/08 Shire Pharmaceuticals Accepted Abbreviated Submission
infliximab (Remicade) 374/07 Schering-Plough Ltd Not Recommended Full submission
infliximab (Remicade) 374/07 Schering-Plough Ltd Not Recommended Non submission
adalimumab (Humira) 800/12 Abbott Laboratories Superseded Non submission
adalimumab (Humira) 824/12 Abbott Laboratories Not Recommended Non submission
budesonide 3mg gastro-resistant capsule (Budenofalk) 828/12 Dr Falk Pharma UK Accepted Full submission
budesonide 9mg gastro-resistant granules (Budenofalk) Abbreviated 831/12 Dr Falk Pharma UK Accepted Abbreviated Submission
adalimumab (Humira) 1208/16 AbbVie Ltd Not Recommended Non submission
budesonide gastro-resistant granules (Budenofalk®) 970/14 Dr Falk Pharma UK Accepted Abbreviated Submission
budesonide 3mg gastro-resistant capsules (Budenofalk) 1043/15 Dr Falk Pharma UK Restricted Full submission
vedolizumab (Entyvio) 1045/15 Takeda UK Ltd Accepted Full submission
vedolizumab (Entyvio) 1064/15 Takeda UK Ltd Restricted Full submission
budesonide (Cortiment) 1093/15 Ferring Pharmaceuticals Ltd Not Recommended Abbreviated Submission
linaclotide (Constella) 869/13 Almirall Ltd Restricted Full submission
adalimumab (Humira) 880/13 AbbVie Ltd Restricted Abbreviated Submission
golimumab (Simponi) 946/13 MSD Superseded Full submission

Back